Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Chronic inflammatory demyelinating polyneuropathy following malignant melanoma.
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.
Slowing of brain atrophy and reductions in new multiple sclerosis lesions sustained at three years in patients treated with Genzyme's LemtradaTM
Effects of Panax ginseng in Neurodegenerative Diseases.
Liver X receptors alpha and beta promote myelination and remyelination in the cerebellum.
Long-term follow-up of vanishing tumors in the brain: How should a lesion mimicking primary CNS lymphoma be managed?
Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair.
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
Treating multiple sclerosis with monoclonal antibodies: a 2013 update.
Evaluation of the 2010 McDonald multiple sclerosis criteria in children with a clinically isolated syndrome.
Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program.
Biplanar MRI for the assessment of the spinal cord in multiple sclerosis.
Considering the influence of stimulation parameters on the effect of conventional and high-definition transcranial direct current stimulation.
Immunohistochemical detection of sphingosine-1-phosphate and sphingosine kinase-1 in human tissue samples.
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.
Epidural blood patch in a patient with multiple sclerosis: is it safe?
Alemtuzumab (Lemtrada) - NICE says yes in final draft guidance
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial.
Infectious causes of multiple sclerosis.
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
Pages
« first
‹ previous
…
117
118
119
120
121
122
123
124
125
…
next ›
last »